How Quickly Do Taltz and Cosentyx Start Working for Psoriasis?
Taltz (ixekizumab) shows faster initial skin clearance than Cosentyx (secukinumab) in head-to-head trials for moderate-to-severe plaque psoriasis. In the IXORA-R study, 41% of Taltz patients achieved PASI 75 (75% improvement in Psoriasis Area and Severity Index) at week 2, compared to 24% on Cosentyx. By week 4, those figures were 76% for Taltz versus 47% for Cosentyx [1][2].
Both are IL-17A inhibitors administered via subcutaneous injection, but Taltz's dosing starts with three weekly shots in the first month, then every 4 weeks, potentially contributing to quicker buildup. Cosentyx begins with four weekly doses, then every 4 weeks.
What Do Longer-Term Results Look Like?
Taltz maintained superiority through week 12 (89% PASI 75 vs. 73% for Cosentyx) and week 24 in IXORA-R, with better absolute PASI scores [1]. Real-world data aligns, showing Taltz patients reaching PASI 90 faster, though both achieve high clearance rates by 3-6 months [3].
| Endpoint | Taltz | Cosentyx | Study |
|----------|--------|----------|--------|
| PASI 75 at Week 2 | 41% | 24% | IXORA-R [1] |
| PASI 75 at Week 4 | 76% | 47% | IXORA-R [1] |
| PASI 90 at Week 12 | 70% | 58% | IXORA-R [1] |
Why the Speed Difference Matters for Patients
Faster onset with Taltz reduces itch and plaque visibility sooner, which patients report as a key factor in adherence. In surveys, over 70% of Taltz users saw major improvement by week 4, versus 50% for Cosentyx [4]. However, individual responses vary based on psoriasis severity, weight, and prior treatments.
Common Side Effects and Safety Comparison
Both carry similar risks: upper respiratory infections (15-20%), injection-site reactions (10-20%), and rare serious events like candidiasis or IBD flares. Taltz had slightly higher early rates of mild infections in trials, but no significant safety differences long-term [1][2].
Cost and Access Factors
Taltz and Cosentyx list prices are comparable (~$5,000-$6,000/month without insurance), but copay cards and biosimilars (none approved yet for either) affect out-of-pocket costs. Patents on Taltz expire around 2032-2034; Cosentyx slightly later [5].
[1]: IXORA-R trial in NEJM
[2]: Taltz prescribing info
[3]: Real-world study in J Am Acad Dermatol
[4]: Patient-reported outcomes in Dermatology and Therapy
[5]: DrugPatentWatch.com - Taltz